Compugen Announces $15 Million Funding Agreement for its Keddem Subsidiary

News   Mar 21, 2013

 
Compugen Announces $15 Million Funding Agreement for its Keddem Subsidiary
 
 
 

RELATED ARTICLES

Psoriasis Drug Also Reduces Aortic Inflammation

News

An antibody used to treat the autoimmune skin disease psoriasis is also effective at reducing aortic inflammation, a key marker of future risk of major cardiovascular events.

READ MORE

Putting the Brain at the Center of Anesthesiology

News

Emery N. Brown explains how statistics and neuroscience improve anesthesiology at the American Association for the Advancement of Science's annual meeting.

READ MORE

Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody Technology

News

Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE